

LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma

Estado Reclutando	Tipo de Participantes Sujetos incapaces de otorgar consentimiento	Rangos de Edad Menores de 18
Género Ambos	Fases Fase III	Participantes esperados 15
Resultados Sin resultados	Bajo nivel intervención No	Enfermedad rara No
Cobertura geográfica Sin determinar	Ámbitos del ensayo tratamiento, seguridad, eficacia	Terapia avanzada NO

Información

Identificador 2023-508101-24-00 (CTIS)	Cod. Protocolo UKM17_0023
--	-------------------------------------

Transicionado 2017-001691-39

Área terapéutica
Enfermedades [C] - Cáncer [C04]

Enfermedad investigada
Lymphoblastic lymphoma

Título Científico
LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma

Justificación

No aportado

Objetivo Principal

The primary objective of the first randomized question (R1) open for all LBL patients (pts) of the core study cohort, is to evaluate whether the cumulative incidence of relapses in the central nervous system can be decreased by substituting prednisone (60 mg/m²/d for 21 days plus a 9 day tapering) (standard arm, SA) by dexamethasone (10 mg/m²/d for 14 days without tapering) (experimental arm, EA) in induction therapy.

The primary objective of the second randomized question (R2) open for high-risk pts of the core study cohort, is to test whether the probability of pEFS can be improved by an intensified treatment arm (EA) compared to the standard treatment arm (SA). In the EA pts receive 2 additional doses of PEG asparaginase during protocol Ib* and an intensified protocol M consisting of one course for high-risk (HR) ALL (HR-1'), followed by one standard high-dose methotrexate (MTX) course, followed by another intense course for HR ALL (HR-2') and a second standard high-dose MTX course.

Variables de Evaluación Primaria

Primary endpoints of randomization 1: For the randomized question 1 the cumulative incidence of relapse with involvement of the CNS (CNS-relapse, pCICR) is the primary endpoint.

Primary endpoints of randomization 2: For the randomized question 2 the estimated probability of event-free survival (pEFS) is the primary endpoint.

Momentos temporales de evaluación primaria

No aportado

Objetivo Secundario

The pEFS and cumulative incidence of relapse/CNS-relapse as compared to study EURO-LB 02

Overall survival (pOS) defined as time from diagnosis to death of any cause or to date of last contact for patients alive as compared to study EURO-LB 02

Treatment related mortality in the randomized arms and compared to study EURO-LB 02

Adverse event and severe adverse event profile in specific protocol elements or randomized arms and during follow-up and compared to study EURO-LB 02

Feasibility and results of risk group stratification

Feasibility of minimal residual disease evaluation in children and adolescents with LBL

Identification of prognostic molecular markers for T-LBL which can be added to the risk group stratification system in a subsequent trial (PTEN mutations and deletions, PIK3CA, PIK3R1, KRAS, NRAS, chromosome 6q alterations, status of TRG locus and further molecular markers identified in the targeted panel of molecular markers for T-LBL)

Variables de Evaluación Secundaria

No aportado

Momentos temporales de evaluación secundaria

No aportado

Criterios de Inclusión

Newly diagnosed lymphoblastic lymphoma Age <18 years at diagnosis Patient enrolled in a participating center Written informed consent of patient (>14 years of age or according to local law and regulation) and parents to trial participation and transfer and processing of data Willingness of patients and the investigator/pathologist to provide adequate slides/blocks for reference (molecular) pathology and international pathology panel and/or fresh or fresh frozen samples for genetic risk group stratification if these samples are available after standard diagnostic procedures.

Criterios de Exclusión

Lymphoblastic lymphoma as secondary malignancy Non-lymphoma related relevant medical, psychiatric or social conditions incompatible with trial treatment including among others : - prior organ transplant - severe immunodeficiency - demyelinating Charcot-Marie Tooth syndrome - serious acute or chronic infections, such as HIV, VZV and tuberculosis - urinary tract infection, cystitis, urinary outflow obstruction, severe renal impairment (e.g. creatinine clearance less than 20 ml/min) - severe hepatic impairment (bilirubin >3 times ULN, transaminases >10 times ULN) - myocardial insufficiency, severe arrhythmias - ulcers of the oral cavity and known active gastrointestinal ulcer disease - known hypersensitivity to any IMP and to any excipient Steroid pre-treatment with 1 mg/kg/d for more than two weeks during the last month before diagnosis Vaccination with live vaccines within 2 weeks before start of protocol Treatment Treatment started according to another protocol or pre-treatment with cytostatic drugs (except INITIAL EMERGENCIES) Participation in another clinical trial that interferes with the protocol, except NHL-BFM Registry 2012 and trials with different endpoints, involving aspects of supportive treatment, which can run parallel to LBL 2018 without influencing the outcome of this trial (e.g. trials on antiemetics, antibiotics, strategies for psychosocial support) Evidence of pregnancy or lactation period Sexually active adolescents not willing to use highly effective contraceptive method (pearl index < 1) until 12 months after end of cytostatic therapy

Calendario

(Última actualización: 18/08/2026)

Autorización 12/03/2019	Inicio de Ensayo 13/09/2019	Inclusión Primer Paciente 02/03/2020	Interrumpido No aportado	Reiniciado No aportado
--	--	---	---	---

Fin de reclutamiento No aportado	Fin prematuro (España) No aportado	Fin prematuro (Global) No aportado	Fin del ensayo en España No aportado	Fin del ensayo global No aportado
---	---	---	---	--

Promotor

Universitaetsklinikum Muenster AöR Germany

Albert-Schweitzer-Campus 1Sentrup

Contact Person

NHL-BFM study center

+492518355696

lbl2018@ukmuenster.de

Monetary support: N/A

Tipo de promotor: No comercial

Ceim

CEIm del Hospital Clínico Universitario de Valencia

Avda. Vicente Blasco Ibáñez, 17 46010 Valencia

ceic_hcv@gva.es

Centros

Activo (28/02/2020)	COMP. HOSPITALARIO B (ANTIGUO HOSPITAL VIRGEN DEL CAMINO)(*) Pamplona/Iruña NAVARRA Pediatría
No iniciado (---/---/----)	Complejo Hospitalario Universitario Insular Materno Infantil Las Palmas De Gran Canaria LAS PALMAS Pediatric oncology
Activo (27/03/2020)	COMPLEJO HOSPITALARIO UNIVERSITARIO INSULAR-MATERO INFANTIL Palmas de Gran Canaria, Las LAS PALMAS Pediatría
Activo (27/03/2020)	COMPLEXO HOSPITALARIO UNIVERSITARIO DE VIGO Vigo PONTEVEDRA Pediatría
Activo (28/02/2020)	HOSPITAL CLINICO UNIVERSITARIO DE SANTIAGO Santiago de Compostela CORUÑA Pediatría
Activo (28/02/2020)	HOSPITAL CLÍNICO UNIVERSITARIO DE VALENCIA Valencia VALENCIA Pediatric Onco-hematology
No iniciado (---/---/----)	Hospital Clinico Universitario De Valladolid Valladolid VALLADOLID Pediatric oncology and hematology department
Activo (28/02/2020)	HOSPITAL CLÍNICO UNIVERSITARIO VIRGEN DE LA ARRIXACA Murcia MURCIA Pediatría

Activo (28/02/2020)

HOSPITAL DE LA SANTA CREU I SANT PAU

Barcelona

BARCELONA

Pediatría

No iniciado (---/---/----

Hospital De La Santa Creu I Sant Pau

Barcelona

BARCELONA

Pediatric oncology and hematology department

Activo (27/03/2020)

HOSPITAL DE SANT JOAN DE DÉU.

Esplugues de Llobregat

BARCELONA

Pediatría

No iniciado (---/---/----

Hospital General Universitario Dr. Balmis

Alicante

ALICANTE

Pediatric oncology and hematology department

Activo (27/03/2020)

HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN

Madrid

MADRID

Pediatría

No iniciado (---/---/----

Hospital Infantil Universitario Nino Jesus

Madrid

MADRID

Pediatric oncology and hematology department

Activo (28/02/2020)

HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESUS

Madrid

MADRID

Onco-hematology

Activo (16/06/2020)

HOSPITAL MATERNO-INFANTIL

Badajoz

BADAJOS

Pediatría

Activo (28/02/2020)

HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE

Valencia

VALENCIA

Onco-hematology

Activo (28/02/2020)

HOSPITAL UNIVERSITARI SON ESPASES

Palma de Mallorca

BALEARES

Pediatría

Activo (27/03/2020)

HOSPITAL UNIVERSITARI VALL D'HEBRON

Barcelona

BARCELONA

Pediatric Onco-hematology

Activo (28/02/2020)

HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS

Oviedo

ASTURIAS

Pediatría

No iniciado (---/---/----)

Hospital Universitario De Badajoz

Badajoz

BADAJOZ

Pediatric oncology and hematology department

Activo (28/02/2020)

HOSPITAL UNIVERSITARIO DE CRUCES

Barakaldo

VIZCAYA/BIZKAIA

Pediatría

No iniciado (---/---/----)

Hospital Universitario De Navarra

Pamplona

NAVARRA

Pediatric oncology

No iniciado (---/---/----)

Hospital Universitario De Toledo

Toledo

TOLEDO

Pediatrics

Activo (28/02/2020)

HOSPITAL UNIVERSITARIO
DONOSTIA-DONOSTIA
UNIBERTSITATE OSPITALEA

Donostia/San Sebastián

GUIPÚZCOA

Pediatría

Activo (28/02/2020)

HOSPITAL UNIVERSITARIO LA PAZ

Madrid

MADRID

Oncology-Hematology

Activo (27/03/2020)

HOSPITAL UNIVERSITARIO MARQUÉS
DE VALDECILLA

Santander

CANTABRIA

Pediatría

Activo (28/02/2020)

HOSPITAL UNIVERSITARIO MIGUEL
SERVET

Zaragoza

ZARAGOZA

Pediatría

Activo (28/02/2020)

HOSPITAL UNIVERSITARIO NUESTRA
SEÑORA DE CANDELARIA

Santa Cruz de Tenerife

STA. CRUZ DE TENERIFE

Pediatría

Activo (28/02/2020)

HOSPITAL UNIVERSITARIO REGIONAL
DE MÁLAGA

Málaga

MÁLAGA

Pediatría

Activo (28/02/2020)

HOSPITAL UNIVERSITARIO
TORRECÁRDENAS

Almería

ALMERÍA

Pediatría

Activo (28/02/2020)

HOSPITAL UNIVERSITARIO VIRGEN DE
LAS NIEVES

Granada

GRANADA

Pediatría

Activo (28/02/2020)

HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO

Sevilla

SEVILLA

Pediatría

Activo (28/02/2020)

HOSPITAL UNIVERSITARIO VIRGEN MACARENA

Sevilla

SEVILLA

Pediatría

Activo (27/03/2020)

HOSPITAL UNIVERSITARIO 12 DE OCTUBRE

Madrid

MADRID

Pediatría

Medicamentos

-
-
INTRAVENOUS USE

Código ATC: L01DB01 - DOXORUBICINA
Principios Activos: N/A

Experimental

-
-
INTRAVENOUS USE

Código ATC: L01XX24 - PEGASPARGASA
Principios Activos: N/A

Experimental

-
-
INTRAVENOUS USE AND ORAL USE

Código ATC: H02AB07 - PREDNISONA
Principios Activos: N/A

Experimental

-
-
INTRAVENOUS USE

Código ATC: L01BA01 - METOTREXATO
Principios Activos: N/A

Experimental

-
-
INTRAVENOUS USE

Código ATC: L01BC01 - CITARABINA
Principios Activos: N/A

Experimental

-
-
INTRATHECAL USE

Código ATC: H02AB06 - PREDNISOLONA
Principios Activos: N/A

Experimental

-
-
INTRAVENOUS USE



Código ATC: L01CA03 - VINDESINA
Principios Activos: N/A

Experimental

-
-
INTRAVENOUS USE

Código ATC: L01AA06 - IFOSFAMIDA
Principios Activos: N/A

Experimental



-
-

INTRA VENOUS USE

Código ATC: L01CA02 - VINCRISTINA
Principios Activos: N/A

Experimental

-
-

INTRA VENOUS USE

Código ATC: L01AA01 - CICLOFOSFAMIDA
Principios Activos: N/A

Experimental

-
-

INTRA VENOUS USE

Código ATC: L01DB02 - DAUNORUBICINA
Principios Activos: N/A

Experimental

-
-

ORAL USE

Código ATC: L01BB03 - TIOGUANINA
Principios Activos: N/A

Experimental

-
-

ORAL USE

Código ATC: L01BB02 - MERCAPTOPURINA
Principios Activos: N/A

Experimental

-
-

INTRA VENOUS USE AND ORAL USE

Código ATC: H02AB02 - DEXAMETASONA
Principios Activos: N/A

Experimental

Sin resultados

LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma

State
Recruiting

Type of participants
Incapable subjects of giving consent

Age Ranges
Less than 18

Gender
Both

Phases
Phase III

Expected Participants
15

Results
No results

Low level of intervention
No

Rare disease
No

Geographic coverage
Undetermined

Areas of the study
treatment, safety, effectiveness

Advanced therapy
NO

Information

Identifier
2023-508101-24-00 (CTIS)

Protocol Code
UKM17_0023

Transitioned 2017-001691-39

Therapeutic area
Diseases [C] - Cancer [C04]

Investigated Disease
Lymphoblastic lymphoma

Scientific Title
LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma

Rationale

Not provided

Main Objective

The primary objective of the first randomized question (R1) open for all LBL patients (pts) of the core study cohort, is to evaluate whether the cumulative incidence of relapses in the central nervous system can be decreased by substituting prednisone (60 mg/m²/d for 21 days plus a 9 day tapering) (standard arm, SA) by dexamethasone (10 mg/m²/d for 14 days without tapering) (experimental arm, EA) in induction therapy.

The primary objective of the second randomized question (R2) open for high-risk pts of the core study cohort, is to test whether the probability of pEFS can be improved by an intensified treatment arm (EA) compared to the standard treatment arm (SA). In the EA pts receive 2 additional doses of PEG asparaginase during protocol Ib* and an intensified protocol M consisting of one course for high-risk (HR) ALL (HR-1'), followed by one standard high-dose methotrexate (MTX) course, followed by another intense course for HR ALL (HR-2') and a second standard high-dose MTX course.

Primary Endpoints

Primary endpoints of randomization 1: For the randomized question 1 the cumulative incidence of relapse with involvement of the CNS (CNS-relapse, pCICR) is the primary endpoint.

Primary endpoints of randomization 2: For the randomized question 2 the estimated probability of event-free survival (pEFS) is the primary endpoint.

Temporary moments of secondary assessment

Not provided

Secondary Objective

The pEFS and cumulative incidence of relapse/CNS-relapse as compared to study EURO-LB 02

Overall survival (pOS) defined as time from diagnosis to death of any cause or to date of last contact for patients alive as compared to study EURO-LB 02

Treatment related mortality in the randomized arms and compared to study EURO-LB 02

Adverse event and severe adverse event profile in specific protocol elements or randomized arms and during follow-up and compared to study EURO-LB 02

Feasibility and results of risk group stratification

Feasibility of minimal residual disease evaluation in children and adolescents with LBL

Identification of prognostic molecular markers for T-LBL which can be added to the risk group stratification system in a subsequent trial (PTEN mutations and deletions, PIK3CA, PIK3R1, KRAS, NRAS, chromosome 6q alterations, status of TRG locus and further molecular markers identified in the targeted panel of molecular markers for T-LBL)

Secondary Endpoints

Not provided

Temporary moments of secondary assessment

Not provided

Inclusion criteria

Newly diagnosed lymphoblastic lymphoma Age <18 years at diagnosis Patient enrolled in a participating center Written informed consent of patient (>14 years of age or according to local law and regulation) and parents to trial participation and transfer and processing of data Willingness of patients and the investigator/pathologist to provide adequate slides/blocks for reference (molecular) pathology and international pathology panel and/or fresh or fresh frozen samples for genetic risk group stratification if these samples are available after standard diagnostic procedures.

Exclusion criteria

Lymphoblastic lymphoma as secondary malignancy Non-lymphoma related relevant medical, psychiatric or social conditions incompatible with trial treatment including among others : - prior organ transplant - severe immunodeficiency - demyelinating Charcot-Marie Tooth syndrome - serious acute or chronic infections, such as HIV, VZV and tuberculosis - urinary tract infection, cystitis, urinary outflow obstruction, severe renal impairment (e.g. creatinine clearance less than 20 ml/min) - severe hepatic impairment (bilirubin >3 times ULN, transaminases >10 times ULN) - myocardial insufficiency, severe arrhythmias - ulcers of the oral cavity and known active gastrointestinal ulcer disease - known hypersensitivity to any IMP and to any excipient Steroid pre-treatment with 1 mg/kg/d for more than two weeks during the last month before diagnosis Vaccination with live vaccines within 2 weeks before start of protocol Treatment Treatment started according to another protocol or pre-treatment with cytostatic drugs (except INITIAL EMERGENCIES) Participation in another clinical trial that interferes with the protocol, except NHL-BFM Registry 2012 and trials with different endpoints, involving aspects of supportive treatment, which can run parallel to LBL 2018 without influencing the outcome of this trial (e.g. trials on antiemetics, antibiotics, strategies for psychosocial support) Evidence of pregnancy or lactation period Sexually active adolescents not willing to use highly effective contraceptive method (pearl index < 1) until 12 months after end of cytostatic therapy

Calendar

(Last Update: 18/08/2026)

Authorization 12/03/2019	Start of Trial 13/09/2019	First patient inclusion 02/03/2020	Halted Not aported	Restarted Not aported
End of recruitment Not aported	Premature end (Spain) Not aported	Premature End (Global) Not aported	Trial end (Spain) Not aported	Trial end (Global) Not aported

Sponsor

Universitaetsklinikum Muenster AöR Germany

Albert-Schweitzer-Campus 1Sentrup

Contact Person

NHL-BFM study center

+492518355696

lbl2018@ukmuenster.de

Monetary support: N/A

Sponsor type: No commercial

Ceim

CEIm del Hospital Clínico Universitario de Valencia

Avda. Vicente Blasco Ibáñez, 17 46010 Valencia

ceic_hcv@gva.es

Sites

Active (28/02/2020)	COMP. HOSPITALARIO B (ANTIGUO HOSPITAL VIRGEN DEL CAMINO)(*) Pamplona/Iruña NAVARRA Pediatría
not initialized (---/---/----)	Complejo Hospitalario Universitario Insular Materno Infantil Las Palmas De Gran Canaria LAS PALMAS Pediatric oncology
Active (27/03/2020)	COMPLEJO HOSPITALARIO UNIVERSITARIO INSULAR-MATerno INFANTIL Palmas de Gran Canaria, Las LAS PALMAS Pediatría
Active (27/03/2020)	COMPLEXO HOSPITALARIO UNIVERSITARIO DE VIGO Vigo PONTEVEDRA Pediatría
Active (28/02/2020)	HOSPITAL CLINICO UNIVERSITARIO DE SANTIAGO Santiago de Compostela CORUÑA Pediatría
Active (28/02/2020)	HOSPITAL CLÍNICO UNIVERSITARIO DE VALENCIA Valencia VALENCIA Pediatric Onco-hematology
not initialized (---/---/----)	Hospital Clinico Universitario De Valladolid Valladolid VALLADOLID Pediatric oncology and hematology department
Active (28/02/2020)	HOSPITAL CLÍNICO UNIVERSITARIO VIRGEN DE LA ARRIXACA Murcia MURCIA Pediatría

Active (28/02/2020)

HOSPITAL DE LA SANTA CREU I SANT PAU

Barcelona

BARCELONA

Pediatría

not initialized (---/---/----)

Hospital De La Santa Creu I Sant Pau

Barcelona

BARCELONA

Pediatric oncology and hematology department

Active (27/03/2020)

HOSPITAL DE SANT JOAN DE DÉU.

Esplugues de Llobregat

BARCELONA

Pediatría

not initialized (---/---/----)

Hospital General Universitario Dr. Balmis

Alicante

ALICANTE

Pediatric oncology and hematology department

Active (27/03/2020)

HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN

Madrid

MADRID

Pediatría

not initialized (---/---/----)

Hospital Infantil Universitario Nino Jesus

Madrid

MADRID

Pediatric oncology and hematology department

Active (28/02/2020)

HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESUS

Madrid

MADRID

Onco-hematology

Active (16/06/2020)

HOSPITAL MATERNO-INFANTIL

Badajoz

BADAJOS

Pediatría

Active (28/02/2020)

HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE

Valencia

VALENCIA

Onco-hematology

Active (28/02/2020)

HOSPITAL UNIVERSITARI SON ESPASES

Palma de Mallorca

BALEARES

Pediatría

Active (27/03/2020)

HOSPITAL UNIVERSITARI VALL D'HEBRON

Barcelona

BARCELONA

Pediatric Onco-hematology

Active (28/02/2020)

HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS

Oviedo

ASTURIAS

Pediatría

not initialized (---/---/----)

Hospital Universitario De Badajoz

Badajoz

BADAJOZ

Pediatric oncology and hematology department

Active (28/02/2020)

HOSPITAL UNIVERSITARIO DE CRUCES

Barakaldo

VIZCAYA/BIZKAIA

Pediatría

not initialized (---/---/----)

Hospital Universitario De Navarra

Pamplona

NAVARRA

Pediatric oncology

not initialized (---/---/----)

Hospital Universitario De Toledo

Toledo

TOLEDO

Pediatrics

Active (28/02/2020)

HOSPITAL UNIVERSITARIO
DONOSTIA-DONOSTIA
UNIBERTSITATE OSPITALEA

Donostia/San Sebastián

GUIPÚZCOA

Pediatría

Active (28/02/2020)

HOSPITAL UNIVERSITARIO LA PAZ

Madrid

MADRID

Oncology-Hematology

Active (27/03/2020)

HOSPITAL UNIVERSITARIO MARQUÉS
DE VALDECILLA

Santander

CANTABRIA

Pediatría

Active (28/02/2020)

HOSPITAL UNIVERSITARIO MIGUEL
SERVET

Zaragoza

ZARAGOZA

Pediatría

Active (28/02/2020)

HOSPITAL UNIVERSITARIO NUESTRA
SEÑORA DE CANDELARIA

Santa Cruz de Tenerife

STA. CRUZ DE TENERIFE

Pediatría

Active (28/02/2020)

HOSPITAL UNIVERSITARIO REGIONAL
DE MÁLAGA

Málaga

MÁLAGA

Pediatría

Active (28/02/2020)

HOSPITAL UNIVERSITARIO
TORRECÁRDENAS

Almería

ALMERÍA

Pediatría

Active (28/02/2020)

HOSPITAL UNIVERSITARIO VIRGEN DE
LAS NIEVES

Granada

GRANADA

Pediatría

Active (28/02/2020)

HOSPITAL UNIVERSITARIO VIRGEN
DEL ROCÍO

Sevilla

SEVILLA

Pediatria

Active (28/02/2020)

HOSPITAL UNIVERSITARIO VIRGEN
MACARENA

Sevilla

SEVILLA

Pediatria

Active (27/03/2020)

HOSPITAL UNIVERSITARIO 12 DE
OCTUBRE

Madrid

MADRID

Pediatria

Medication

-
-

INTRAVENOUS USE

ATC code: L01DB01 - DOXORUBICINA

Active Principles: N/A

Experimental

-
-

INTRAVENOUS USE

ATC code: L01XX24 - PEGASPARGASA

Active Principles: N/A

Experimental

-
-

INTRAVENOUS USE AND ORAL USE

ATC code: H02AB07 - PREDNISONA

Active Principles: N/A

Experimental

-
-

INTRAVENOUS USE

ATC code: L01BA01 - METOTREXATO

Active Principles: N/A

Experimental

-
-

INTRAVENOUS USE

ATC code: L01BC01 - CITARABINA

Active Principles: N/A

Experimental

-
-

INTRATHECAL USE

ATC code: H02AB06 - PREDNISOLONA

Active Principles: N/A

Experimental

-
-

INTRAVENOUS USE

ATC code: L01CA03 - VINDESINA

Active Principles: N/A

Experimental



-
-

INTRAVENOUS USE

ATC code: L01AA06 - IFOSFAMIDA

Active Principles: N/A

Experimental



-
-

INTRAVENOUS USE

ATC code: L01CA02 - VINCISTINA

Active Principles: N/A

Experimental

-
-

INTRAVENOUS USE

ATC code: L01AA01 - CICLOFOSFAMIDA

Active Principles: N/A

Experimental

-
-

INTRAVENOUS USE

ATC code: L01DB02 - DAUNORUBICINA

Active Principles: N/A

Experimental

-
-

ORAL USE

ATC code: L01BB03 - TIOGUANINA

Active Principles: N/A

Experimental

-
-

ORAL USE

ATC code: L01BB02 - MERCAPTOPURINA

Active Principles: N/A

Experimental

-
-

INTRAVENOUS USE AND ORAL USE

ATC code: H02AB02 - DEXAMETASONA

Active Principles: N/A

Experimental

No results